Timeline of Accomplishments

Year	Accomplishment
1976	Dr. Schwartz introduced the use of selective arteriography and transcatheter embolization techniques for the control of massive post-partum hemorrhage.
1978	Dr. Arnold Eisenfeld and Dr. Peter Schwartz reported the first series of epithelial ovarian cancers demonstrating the presence of estrogen receptor proteins.
1979	Dr. Schwartz is the first to use neo-adjuvant chemotherapy to manage late stage ovarian cancer.
1981	Dr. Schwartz demonstrated for the first time the use of serum alpha fetoprotein for monitoring the treatment of women with ovarian yolk sac tumors.
1982	Dr. Schwartz reported the first series of patients with recurrent ovarian cancers who were treated with tamoxifen, based on their steroid receptor content.
1984	Dr. Schwartz was the first to demonstrate that using combination chemotherapy not only cures women with dysergerminomas but preserves their fertility.
1989	First to report a prospective randomized trial that incorporated hormonal therapy in combination with chemotherapy for the treatment of advanced epithelial ovarian cancer.
1990	Dr. Schwartz establishes the Yale Ovarian Cancer Early Detection Program - the first of its kind in the United States.
1999	Drs. Rutherford and Mor describe differential expression of estrogen receptors in ovarian cancer cells.
2003	Drs. Schwartz, Mor and Rutherford found Discovery to Cure.
2003	Dr. Mor establishes the Discovery to Cure High School Internship Program to encourage students to pursue careers in science, research and medicine.
2004	Dr. Mor's laboratory characterize phenoxodiol as a chemo sencitizer.
2004	Dr. Mor's laboratory identify two different types of ovarian cancer cells within tumors.
2005	Dr. Rutherford is selected as the PI for a phase III clinical trial to test phenoxodiol.
2005	A new panel of markers for the early detection for ovarian cancer is developed by Drs. Mor and Ward.
2007	Dr. Mor's lab and Dr. Silasi identify MyD88 as a marker for paclitaxel resistance allowing appropriate selection of chemotherapy for patients who would not benefit from paclitaxel treatment.
2008	Dr. Ratner establishes SIMS Clinic in partnership with Dr. MaryJane Minkin, sexuality and menopause physician, to help patients who undergo surgery, chemotherapy and radiation, regain intimacy in their lives during and after treatment.
2009	Dr. Mor's laboratory isolated and cloned ovarian cancer stem cells.
2009	NCI/NIH awarded two RO1 grants to Drs. Mor and Alvero to continue work originally supported by the DTC program.
2010	Dr. Alvero from Dr. Mor's laboratory identify ovarian cancer stem cells as the source of chemo resistance.
2010	Immunological and molecular biomarkers of serous carcinoma for diagnosis and potential therapeutic interventions.
2011	Based on Dr. Santin's research, emerge as leaders in the field of diagnosis and management of Uterine-serous-carcinoma (USC), a rare but highly aggressive variant of endometrial cancer. Although it represents only 10% of all endometrial cancer cases, USC accounts for up to 40% of all endometrial cancer-related death.The efficacy of Dr. Santin's novel treatment approach- introducing trastuzumab (anti-HER2/neu-antibody) in combination with chemotherapy in USC patients- is being evaluated in a large, (16 sites) multicenter-study. (clinicaltrials.gov/ct2/show/NCT01367002).
2011	Based on Dr. Azodi's work, emerged as leaders in the field of robotic surgery and minimally invasive approach to managing cancer.
2012	The Discovery to Cure High School Internship Program is awarded a NIH grant for five years.
2012	Dr. Mor established a New Drug Discovery Program for screening the eficacy of new compounds on ovarian cancer stem cells.
2013	Woman to Woman Program is established to provide peer mentoring support to women newly diagnosed with ovarian cancer. The program was expanded in 2014 to include all types of women's reproductive cancer. Both new patients and mentors, who have already been through treatment, benefit from the program.
2014	CanTx is established as a join venture between Yale and industry for the development of new therapies targeting ovarian cancer stem cells.
2014	Established New Advisory Board with organizational structure.